Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Sotagliflozin

  • Home
  • Sotagliflozin
Redefining Risk in Diabetic Kidney Disease: The 2022 AHA/ACC/HFSA Heart Failure Staging and the Efficacy of Sotagliflozin
Posted inClinical Updates Diabetes & Endocrinology news

Redefining Risk in Diabetic Kidney Disease: The 2022 AHA/ACC/HFSA Heart Failure Staging and the Efficacy of Sotagliflozin

Posted by MedXY By MedXY 03/20/2026
This review analyzes the prognostic value of the 2022 Heart Failure staging in patients with diabetes and kidney disease, highlighting the high risk of asymptomatic 'Pre-HF' and the consistent therapeutic benefits of sotagliflozin across all disease stages.
Read More
  • Parkinson’s Disease Genetics Across Diverse Ancestries: An Observational Genetic Study of Causal and Risk Variants with Translational Implications
  • Prognostic Stratification and Outcomes in Brain Metastases from Nonanaplastic Follicular Cell-Derived Thyroid Carcinoma: Insights from a Multicenter Retrospective Study
  • Metabolic Implications of Hepatic, Pancreatic, and Abdominal Fat Depots in Asian Indians Across Normoglycaemia, Prediabetes, and Type 2 Diabetes
  • Once-Weekly Somapacitan: A New Frontier in Growth Hormone Therapy for Girls with Turner Syndrome
  • Melatonin’s Impact on Glucose Metabolism: Risk Amplified by MTNR1B Diabetes Variant
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in